|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo
B, Chien R, Wang YV, Tsai CY, Wu G, et al: Novel small molecules
disrupting Hec1/Nek2 interaction ablate tumor progression by
triggering Nek2 degradation through a death-trap mechanism.
Oncogene. 34:1220–1230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fang Y and Zhang X: Targeting NEK2 as a
promising therapeutic approach for cancer treatment. Cell Cycle.
15:895–907. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhong X, Guan X, Liu W and Zhang L:
Aberrant expression of NEK2 and its clinical significance in
non-small cell lung cancer. Oncol Lett. 8:1470–1476. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ning Z, Wang A, Liang J, Liu J, Zhou T,
Yan Q and Wang Z: Abnormal expression of Nek2 in pancreatic ductal
adenocarcinoma: A novel marker for prognosis. Int J Clin Exp
Pathol. 7:2462–2469. 2014.PubMed/NCBI
|
|
7
|
Jeong AL, Lee S, Park JS, Han S, Jang CY,
Lim JS, Lee MS and Yang Y: Cancerous inhibitor of protein
phosphatase 2A (CIP2A) protein is involved in centrosome separation
through the regulation of NIMA (never in mitosis gene A)-related
kinase 2 (NEK2) protein activity. J Biol Chem. 289:28–40. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wubetu GY, Morine Y, Teraoku H, Yoshikawa
M, Ishikawa D, Yamada S, Ikemoto T, Saito YU, Imura S and Shimada
M: High NEK2 expression is a predictor of tumor recurrence in
hepatocellular carcinoma patients after hepatectomy. Anticancer
Res. 36:757–762. 2016.PubMed/NCBI
|
|
9
|
Li G, Zhong Y, Shen Q, Zhou Y, Deng X, Li
C, Chen J, Zhou Y and He M: NEK2 serves as a prognostic biomarker
for hepatocellular carcinoma. Int J Oncol. 50:405–413. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo Y, Wang J, Zhang L, Shen S, Guo R,
Yang Y, Chen W, Wang Y, Chen G and Shuai X: Theranostical
nanosystem-mediated identification of an oncogene and highly
effective therapy in hepatocellular carcinoma. Hepatology.
63:1240–1255. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Zhang JX, Huang LL, He LJ, Liao
YJ, Lai YR, Deng HX, Tian XP, Kung HF, Xie D, et al: Low expression
of BARX2 in human primary hepatocellular carcinoma correlates with
metastasis and predicts poor prognosis. Hepatol Res. 45:228–237.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang LL, Zhang Y, Zhang JX, He LJ, Lai
YR, Liao YJ, Tian XP, Deng HX, Liang YJ, Kung HF, et al:
Overexpression of NKX6.1 is closely associated with progressive
features and predicts unfavorable prognosis in human primary
hepatocellular carcinoma. Tumour Biol. 36:4405–4415. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cappello P, Blaser H, Gorrini C, Lin DC,
Elia AJ, Wakeham A, Haider S, Boutros PC, Mason JM, Miller NA, et
al: Role of Nek2 on centrosome duplication and aneuploidy in breast
cancer cells. Oncogene. 33:2375–2384. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marina M and Saavedra HI: Nek2 and Plk4:
Prognostic markers, drivers of breast tumorigenesis and drug
resistance. Front Biosci (Landmark Ed). 19:352–365. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barbagallo F, Paronetto MP, Franco R,
Chieffi P, Dolci S, Fry AM, Geremia R and Sette C: Increased
expression and nuclear localization of the centrosomal kinase Nek2
in human testicular seminomas. J Pathol. 217:431–441. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
de Vos S, Hofmann WK, Grogan TM, Krug U,
Schrage M, Miller TP, Braun JG, Wachsman W, Koeffler HP and Said
JW: Gene expression profile of serial samples of transformed B-cell
lymphomas. Lab Invest. 83:271–285. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeng YR, Han ZD, Wang C, Cai C, Huang YQ,
Luo HW, Liu ZZ, Zhuo YJ, Dai QS, Zhao HB, et al: Overexpression of
NIMA-related kinase 2 is associated with progression and poor
prognosis of prostate cancer. BMC Urol. 15:902015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang MX, Xu XM, Zhang P, Han NN, Deng JJ,
Yu TT, Gan YY, He XQ and Long ZX: Effect of silencing NEK2 on
biological behaviors of HepG2 in human hepatoma cells and MAPK
signal pathway. Tumour Biol. 37:2023–2035. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou W, Yang Y, Xia J, Wang H, Salama ME,
Xiong W, Xu H, Shetty S, Chen T, Zeng Z, et al: NEK2 induces drug
resistance mainly through activation of efflux drug pumps and is
associated with poor prognosis in myeloma and other cancers. Cancer
Cell. 23:48–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kokuryo T, Hibino S, Suzuki K, Watanabe K,
Yokoyama Y, Nagino M, Senga T and Hamaguchi M: Nek2 siRNA therapy
using a portal venous port-catheter system for liver metastasis in
pancreatic cancer. Cancer Sci. 107:1315–1320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu SM, Lin SL, Lee KY, Chuang HC, Feng PH,
Cheng WL, Liao CJ, Chi HC, Lin YH, Tsai CY, et al: Hepatoma cell
functions modulated by NEK2 are associated with liver cancer
progression. Int J Cancer. 140:1581–1596. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Neal CP, Fry AM, Moreman C, McGregor A,
Garcea G, Berry DP and Manson MM: Overexpression of the Nek2 kinase
in colorectal cancer correlates with beta-catenin relocalization
and shortened cancer-specific survival. J Surg Oncol. 110:828–838.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang ZC, Gao Q, Shi JY, Guo WJ, Yang LX,
Liu XY, Liu LZ, Ma LJ, Duan M, Zhao YJ, et al: Protein tyrosine
phosphatase receptor S acts as a metastatic suppressor in
hepatocellular carcinoma by control of epithermal growth factor
receptor-induced epithelial-mesenchymal transition. Hepatology.
62:1201–1214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Das TK, Dana D, Paroly SS, Perumal SK,
Singh S, Jhun H, Pendse J, Cagan RL, Talele TT and Kumar S:
Centrosomal kinase Nek2 cooperates with oncogenic pathways to
promote metastasis. Oncogenesis. 2:e692013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pedersen EA, Menon R, Bailey KM, Thomas
DG, Van Noord RA, Tran J, Wang H, Qu PP, Hoering A, Fearon ER, et
al: Activation of Wnt/β-catenin in Ewing sarcoma cells antagonizes
EWS/ETS function and promotes phenotypic transition to more
metastatic cell states. Cancer Res. 76:5040–5053. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi W, Ye Z, Zhuang L, Li Y, Shuai W, Zuo
Z, Mao X, Liu R, Wu J, Chen S, et al: Olfactomedin 1 negatively
regulates NF-κB signalling and suppresses the growth and metastasis
of colorectal cancer cells. J Pathol. 240:352–365. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu C, Li Y, Xing Y, Cao B, Yang F, Yang
T, Ai Z, Wei Y and Jiang J: The interaction between cancer stem
cell marker CD133 and Src protein promotes focal sdhesion kinase
(FAK) phosphorylation and cell migration. J Biol Chem.
291:15540–15550. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin X, Li HR, Lin XF, Yu ME, Tu XW, Hua
ZD, Lin M, Xu NL, Han LL and Chen YS: Silencing of Livin inhibits
tumorigenesis and metastasis via VEGF and MMPs pathway in lung
cancer. Int J Oncol. 47:657–667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang X, Liu X, Luo J, Xiao W, Ye X, Chen
M, Li Y and Zhang GJ: Notch3 inhibits epithelial-mesenchymal
transition by activating Kibra-mediated Hippo/YAP signaling in
breast cancer epithelial cells. Oncogenesis. 5:e2692016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Adriaens C, Standaert L, Barra J, Latil M,
Verfaillie A, Kalev P, Boeckx B, Wijnhoven PW, Radaelli E, Vermi W,
et al: p53 induces formation of NEAT1 lncRNA-containing
paraspeckles that modulate replication stress response and
chemosensitivity. Nat Med. 22:861–868. 2016. View Article : Google Scholar : PubMed/NCBI
|
